TrimRX | AOD-9604 Complete Guide: Benefits, Dosing, Side Effects & Research

Introduction

AOD-9604 is a synthetic peptide built from the last 16 amino acids of the human growth hormone (hGH) molecule (residues 177-191). It was designed by Monash University researchers in the 1990s to keep the fat-burning region of hGH while stripping out the parts of the molecule responsible for growth, insulin resistance and IGF-1 production. The idea was simple. Get the lipolytic punch of growth hormone without the side effects.

The peptide spent years in clinical development with the biotech company Metabolic Pharmaceuticals as a candidate obesity drug. Phase 2b results published around 2007 showed it was safe in humans but failed to beat placebo on weight loss at 24 weeks. Development stalled. Yet AOD-9604 never disappeared. It now circulates widely in the peptide therapy and longevity world, often stacked with GLP-1 medications like semaglutide and tirzepatide or used for cartilage and joint applications based on a separate body of preclinical work.

This guide pulls together what the published research actually shows, what reasonable dosing looks like, and where the evidence gets thin. It is not a marketing pitch. The peptide has real mechanisms worth understanding and real limitations worth respecting.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is AOD-9604?

AOD-9604 is a synthetic 16-amino-acid peptide modeled on the C-terminal end of human growth hormone, with an added tyrosine residue at the N-terminus to improve stability. The full sequence is Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. Frank Ng and colleagues at Monash University Department of Biochemistry first reported its lipolytic activity in the late 1990s.

Quick Answer: AOD-9604 is amino acid residues 177-191 of human growth hormone, a 16-amino-acid lipolytic fragment

Growth hormone is a 191-amino-acid protein with multiple functional domains. The N-terminal region drives growth and IGF-1 production. The C-terminal region drives lipolysis (fat breakdown) and inhibits lipogenesis (fat storage). By isolating residues 177-191, the AOD molecule was supposed to capture the metabolic effects of growth hormone on fat tissue without affecting blood sugar, insulin signaling or long bone growth.

Metabolic Pharmaceuticals licensed the molecule and pursued it as an oral obesity drug. After multiple Phase 1 and Phase 2 studies, development was discontinued around 2007 because of inadequate weight loss results. The peptide later moved into a different commercial path. Phosphagenics and other groups studied it for osteoarthritis through intra-articular injection. In 2014 an independent expert panel concluded AOD-9604 was Generally Recognized as Safe (GRAS) for use in functional foods at low doses. In the US it is now sold by compounding pharmacies and research peptide vendors without FDA approval for any therapeutic indication.

How Does AOD-9604 Work in the Body?

AOD-9604 acts on adipocytes (fat cells) by stimulating lipolysis and inhibiting lipogenesis. The current best model is that it works through a beta-3 adrenergic receptor pathway in adipose tissue rather than through the classical growth hormone receptor. This is the key distinction from full-length hGH. Heffernan and colleagues (2001 Endocrinology) showed AOD-9604 increased lipolysis in isolated rat adipocytes and reduced body fat in genetically obese (ob/ob) mice without changing IGF-1 levels.

Several follow-up papers extended this. Studies in 3T3-L1 cells showed AOD-9604 reduced triglyceride accumulation during adipocyte differentiation. In rodent models, chronic dosing increased oxygen consumption and energy expenditure modestly. The peptide does not appear to suppress appetite, which is the dominant mechanism of GLP-1 drugs like semaglutide. Its mechanism is peripheral, acting on the fat cell itself.

A separate preclinical line of work looks at chondrocytes (cartilage cells). Studies by Kwan et al. and others suggested AOD-9604 can stimulate proteoglycan synthesis and may help cartilage repair in animal osteoarthritis models. This is the basis for joint-related claims in the peptide market, though human data remains limited.

What Does the Clinical Evidence Show for Fat Loss?

The strongest test of AOD-9604 for weight loss was a 24-week randomized double-blind placebo-controlled trial by Ng and colleagues published in Obesity in 2008. The trial enrolled 536 obese adults across multiple Australian sites. Participants received daily oral AOD-9604 at 1, 5, 10, 25 or no peptide alongside a standard calorie-restricted diet. The primary endpoint was change in body weight at week 12.

The results were disappointing. None of the AOD-9604 dose groups achieved statistically significant weight loss over placebo at 24 weeks. There was a small early benefit at 12 weeks in some dose arms (around 2.6 kg vs 0.8 kg for placebo at the 1 mg dose), but this faded as the trial continued. The investigators concluded oral AOD-9604 did not produce clinically meaningful weight loss.

Smaller earlier trials had hinted at metabolic effects. A Phase 2a study reported in 2006 found increased fat oxidation on indirect calorimetry after a single 9 mg oral dose. Subcutaneous administration was studied less rigorously in humans. There are no large published trials of injected AOD-9604 for weight loss. Most claims about the injected form come from preclinical data and small open-label observations.

So the bottom line on monotherapy fat loss is sober. The molecule shows lipolytic activity in cells and animals. It failed to beat placebo in the only adequately powered human trial. Anyone claiming AOD-9604 alone produces semaglutide-level weight loss is going past the evidence.

What Does the Research Show for Cartilage and Joint Repair?

The joint health story rests mostly on animal and in vitro studies. Researchers at Phosphagenics and academic groups have shown AOD-9604 can stimulate chondrocyte proliferation and matrix synthesis in cell culture. In rabbit and rat models of induced osteoarthritis, intra-articular AOD-9604 reduced cartilage damage scores and improved joint function compared to control injections.

The most cited human work in this area comes from small case series and unpublished clinical observations from Australian sports medicine practices. A 2010-era Phosphagenics-sponsored study tested AOD-9604 combined with hyaluronic acid in a small group of osteoarthritis patients and reported pain reduction over 12 weeks. The trial was small and not placebo controlled in a way that supports broad clinical conclusions.

By contrast, peptides like BPC-157 and TB-500 have more anecdotal use in the joint and tendon space but also lack large randomized trials. AOD-9604 sits in the same category. Promising biology, thin human evidence. If you are considering it for a joint indication, recognize that the clinical case rests on preclinical work plus practitioner observation.

Does AOD-9604 Affect IGF-1 or Blood Sugar?

One of the design goals of AOD-9604 was to keep the fat-burning effects of growth hormone while avoiding the metabolic downsides. Full-length recombinant hGH raises IGF-1, can worsen insulin sensitivity and is contraindicated in diabetes and active malignancy. Long-term hGH use also raises concerns about cancer risk and tissue overgrowth.

Published trials of AOD-9604 in humans found no significant change in serum IGF-1, fasting glucose or insulin compared to placebo. Ng et al. (2008) measured these endpoints carefully and reported no signal of growth hormone-like effects on the somatotropic axis. This is biologically consistent with the peptide design. The C-terminal fragment does not bind the growth hormone receptor with high affinity, so the IGF-1 cascade is not activated.

For people who cannot use full hGH because of diabetes or cancer history, this safety profile is the main appeal of AOD-9604. The trade-off is that the lipolytic effect is much weaker than full hGH and the weight loss benefit in humans is unproven.

What Is a Typical AOD-9604 Dosing Protocol?

There is no FDA-approved dose because there is no FDA-approved indication. The doses used in published human trials ranged widely. Oral doses studied went from 1 mg up to 25 mg daily. The peptide is poorly absorbed orally, which is part of why later use shifted toward subcutaneous injection. Most compounded subcutaneous protocols sold today use 250-300 mcg per day, sometimes pushed to 500 mcg, given by subcutaneous injection morning or pre-fasted cardio.

Common practitioner protocols look like this. A 12-week cycle at 300 mcg subcutaneous daily, usually fasted in the morning, followed by a 4 week break. Some clinicians dose 5 days on, 2 days off. None of these schedules have been validated in randomized trials. They are empirical and based on extrapolation from preclinical lipolysis data.

If a clinician offers AOD-9604, ask three questions. Where does the peptide come from (503A or 503B compounding pharmacy with USP-grade material). What is the dose and frequency and why. What outcome are you tracking and over what time window. Reasonable expectations are modest changes in body composition over months, not dramatic weight loss in weeks.

What Are the Side Effects and Safety Concerns?

In published trials AOD-9604 was well tolerated. Ng et al. (2008) reported adverse event rates similar to placebo. Injection site reactions are the most common practical issue with the subcutaneous form. Mild headache, nausea and fatigue have been reported anecdotally but were not signals in randomized data.

The safety database is shallow compared with FDA-approved drugs. The Ng trial of 536 patients is the largest. Long-term safety beyond 24 weeks is not well characterized in humans. Pregnancy, breastfeeding and pediatric use are not studied. People with active cancer, uncontrolled diabetes or pituitary disease should not use the peptide without specialist input, even though the IGF-1 data is reassuring.

Quality control is the real risk in the current market. Research peptide vendors are not regulated. Compounded products from licensed 503A or 503B pharmacies have far better quality assurance than online research-grade vials. If you are going to use AOD-9604, use a properly compounded product through a licensed prescriber and pharmacy.

Key Takeaway: The FDA has not approved AOD-9604 for any indication; it was given GRAS food-additive status in 2014 by an independent expert panel

How Does AOD-9604 Compare with GLP-1 Medications?

The mechanism comparison is the cleanest way to think about this. Semaglutide (the active ingredient in Ozempic® and Wegovy®) and tirzepatide (Mounjaro® and Zepbound®) work centrally on appetite, gastric emptying and reward pathways through GLP-1 and GIP receptors. They produce profound caloric intake reduction and large weight loss. STEP 1 (Wilding et al. 2021 NEJM) showed 14.9% body weight reduction with semaglutide at 68 weeks. SURMOUNT-1 (Jastreboff et al. 2022 NEJM) showed 20.9% with tirzepatide at 72 weeks.

AOD-9604 works peripherally on the fat cell. It does not change appetite or food intake. In the only large human trial it did not beat placebo. So the two classes are not in the same tier for fat loss. Telehealth platforms like TrimRx that provide compounded semaglutide and tirzepatide are working with molecules supported by Phase 3 cardiovascular outcomes trials. AOD-9604 sits in a different evidence category entirely.

That said, the peptide is sometimes combined with GLP-1 therapy for a different reason. People on semaglutide or tirzepatide lose meaningful lean mass alongside fat mass. Some practitioners use peripheral lipolytic peptides plus growth hormone secretagogues like ipamorelin to try to bias loss toward fat tissue. The evidence for this strategy in humans is preclinical and observational rather than randomized.

What Lab Work Should You Track on AOD-9604?

Baseline labs before starting should include fasting glucose, HbA1c, fasting insulin, IGF-1, complete metabolic panel, lipid panel and a thyroid panel (TSH and free T4). DEXA body composition is the gold standard for tracking fat mass change. Waist circumference and bioimpedance are reasonable second-line tools.

Repeat at 12 weeks. Look for change in fat mass on DEXA, change in waist circumference, change in lipid panel (HDL and triglycerides often improve with lipolysis), and stability in IGF-1 and fasting glucose. If IGF-1 rises significantly, something is off. AOD-9604 should not do that, so a significant rise suggests contamination or a different peptide than labeled.

If after 12 weeks of consistent dosing you cannot document any change on DEXA or lipid markers, the honest assessment is the peptide is not doing much for you. Continuing for longer is unlikely to change that.

Is AOD-9604 Legal in the US?

The legal status is layered. AOD-9604 is not an FDA-approved drug for any indication. The independent GRAS notification covered low-dose use in functional foods, not therapeutic injection. Subcutaneous injection of compounded AOD-9604 for weight loss or joint health is off-label use of a non-approved substance.

It can be obtained through licensed compounding pharmacies that hold raw material with USP-grade certificates of analysis. The legal posture depends on the state, the practitioner’s prescribing scope and the pharmacy’s accreditation. Research peptide vendors selling vials labeled “not for human use” are operating in a different and far riskier space.

The peptide is on the World Anti-Doping Agency prohibited list. Competitive athletes in WADA-tested sports should not use AOD-9604.

What Does the Future Research Pipeline Look Like?

There is no major active Phase 3 program for AOD-9604 in any indication. The drug development arc essentially ended after the 2008 obesity trial failure. Some smaller groups continue cartilage repair work in preclinical models. Phosphagenics evaluated alternative delivery systems for joint applications.

The big movement in obesity research has shifted to GLP-1 and GLP-1 combination biology. Drugs like retatrutide (GLP-1, GIP, glucagon triple agonist), survodutide, orforglipron and CagriSema are showing 20% plus weight loss in Phase 2 and 3 trials. AOD-9604 cannot compete in that space and is unlikely to return as a serious obesity candidate.

The peptide will probably continue as an adjunct molecule in compounded and longevity practice, supported more by mechanism and tradition than by new trial data. If a randomized trial of subcutaneous AOD-9604 plus GLP-1 versus GLP-1 alone is ever run, that would be the most informative future study.

How Does TrimRx Fit Into Peptide and Weight Loss Care?

TrimRx is a telehealth platform focused on FDA-active-ingredient compounded medications for weight management, primarily semaglutide and tirzepatide. The clinical model is conservative and evidence-based. The free assessment quiz on the TrimRx site matches each patient to a clinician-reviewed treatment plan based on health history, BMI and goals.

We do not currently offer AOD-9604 as part of our standard formulary. The reason is the evidence gap. Our protocols stay close to molecules with Phase 3 randomized trial data and FDA pathways. For people interested in adjunct peptide therapy, working with a peptide-focused practitioner alongside GLP-1 treatment is a reasonable approach, but the foundation of meaningful fat loss in 2026 is still GLP-1 or dual agonist therapy.

If you are starting from a place of significant excess body weight and want the highest-yield intervention, that is where the data sits. Adjunct peptides like AOD-9604 may have a place in fine-tuning body composition once the heavy lifting of GLP-1 induced weight loss is underway, but they are not a substitute for the primary therapy.

Bottom line: Typical compounded protocols use 300 mcg subcutaneous daily, though no published dose-response data supports this exact number

FAQ

Is AOD-9604 the Same as Growth Hormone?

No. AOD-9604 is a 16-amino-acid fragment of growth hormone, specifically residues 177-191 with an added tyrosine. Full human growth hormone is 191 amino acids. AOD-9604 keeps the lipolytic region but lacks the parts that bind the growth hormone receptor strongly, so it does not raise IGF-1 or affect insulin sensitivity the way full hGH does.

How Much Weight Can You Lose on AOD-9604 Alone?

Based on the Ng et al. 2008 Obesity trial of 536 patients, oral AOD-9604 did not produce statistically significant weight loss versus placebo at 24 weeks. Subcutaneous protocols are not validated in large trials. Realistic expectations are modest body composition changes over months, not the 14-20% weight loss seen with semaglutide and tirzepatide.

Can AOD-9604 Help Osteoarthritis Pain?

Preclinical animal and in vitro studies suggest AOD-9604 can stimulate chondrocyte activity and reduce cartilage damage. Human evidence is limited to small uncontrolled series. It is not FDA approved for osteoarthritis. If you are considering it for joint pain, see a sports medicine or orthopedic specialist and weigh it against options with better evidence such as physical therapy, weight loss, NSAIDs or hyaluronic acid injection.

How Is AOD-9604 Administered?

The two main routes are oral (used in the Metabolic Pharmaceuticals Phase 2 trials) and subcutaneous injection (used in current compounded protocols). Oral bioavailability is poor, which contributed to the trial failures. Subcutaneous injection has better pharmacokinetics but no large trial data behind it. Intra-articular injection has been studied for joint applications in animals.

Will AOD-9604 Mess up My Blood Sugar?

In published human trials there was no signal of changes in fasting glucose, HbA1c or insulin sensitivity. The peptide does not bind the growth hormone receptor strongly enough to trigger the insulin resistance seen with full hGH. People with diabetes or prediabetes should still monitor labs while using it.

Is AOD-9604 Legal to Buy Online?

Buying research-grade peptides labeled “not for human use” from online vendors is legally and quality-risky. The safer path is a prescription through a licensed clinician with the peptide compounded by a 503A or 503B pharmacy using USP-grade raw material. The peptide is on the WADA prohibited list for competitive athletes.

How Long Until You See Results with AOD-9604?

If there are going to be measurable effects on body composition, they would show up over 8-12 weeks on consistent dosing, ideally tracked with DEXA. If after 12 weeks no change shows up, continuing longer is unlikely to help. Joint applications, if any, also need at least 8-12 weeks to evaluate.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.

AOD-9604 Complete Guide: Benefits, Dosing, Side Effects & Research

Table of Contents